We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Instrumentation Laboratory Introduces Fully Automated HemosIL® AcuStar HIT Assay Panel in Europe and International Regions
Product News

Instrumentation Laboratory Introduces Fully Automated HemosIL® AcuStar HIT Assay Panel in Europe and International Regions

Instrumentation Laboratory Introduces Fully Automated HemosIL® AcuStar HIT Assay Panel in Europe and International Regions
Product News

Instrumentation Laboratory Introduces Fully Automated HemosIL® AcuStar HIT Assay Panel in Europe and International Regions


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Instrumentation Laboratory Introduces Fully Automated HemosIL® AcuStar HIT Assay Panel in Europe and International Regions"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

HemosIL AcuStar HIT assays are the first on-demand, fully automated, chemiluminescent reagents on a hemostasis testing system for the detection of antibodies associated with Heparin-Induced Thrombocytopenia (HIT). They provide enhanced detection of HIT antibodies in specialty and hospital hemostasis laboratories. Unlike existing manual processes, the ready-to-use, cartridge-based assays offer results in approximately 30 minutes -- on-demand, 24/7 -- allowing clinicians to make timely, well-informed therapeutic decisions. In addition, pre-calibrated reagent cartridges offer significant time- and cost- efficiencies. Chemiluminescent technology provides analytical excellence through an expansive working range for high sensitivity and precision.

"We are proud to be at the forefront of HIT testing solutions," said Remo Tazzi, Director of Hemostasis Marketing at IL. "Arming healthcare providers with better diagnostic tools is our mission, and this test panel is an excellent example of that. Now, management decisions for patients at risk for HIT can be made faster and more effectively than ever before, leading to significant time- and cost-efficiencies, as well as enhanced patient care."

This is the second panel of assays that has been commercialized on the ACL AcuStar system. The first is the highly sensitive, fully automated Antiphospholipid Syndrome (APS) panel. The assays in this panel provide a full clinical picture to distinguish APS and other thrombotic disorders efficiently and effectively, 24/7. APS is one of the most common autoimmune diseases, occurring in 1-5% of the general population. Clinical manifestations include vascular thrombosis and related sequelae (eg, stroke, pulmonary embolism, myocardial infarction) and pregnancy complications. While approximately 10-15% of these events result from APS, there are many other conditions to consider when determining root cause. Therefore, accurate and rapid diagnosis is essential when managing these critically ill patients.

Advertisement